C12N 2015/8572
Animal models for proliferative diseases
Official title: {Animal models for proliferative diseases, e.g. comprising an oncogene}
C12N2015/8572 (Animal models for proliferative diseases) appears on 37 US grants and 50 published applications in this corpus.
Search patents in C12N- Granted patents
- 37
- Published applications
- 50
- Assignees
- 27
- Inventors
- 95
- Latest grant
- 3 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 2 |
| 2015 | 2 | 2 |
| 2016 | 2 | 4 |
| 2017 | 3 | 5 |
| 2018 | 3 | 5 |
| 2019 | 4 | 16 |
| 2020 | 0 | 3 |
| 2021 | 6 | 3 |
| 2022 | 11 | 4 |
| 2023 | 0 | 3 |
| 2024 | 3 | 0 |
| 2025 | 1 | 1 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Chimeric antigen receptors targeted to PSCA3 Mar 2026US 12,565,535 B2City of Hope
- Inducible modification of a cell genome30 Dec 2025US 12,509,702 B2AstraZeneca AB
- Non-human animals having a humanized signal-regulatory protein gene10 Dec 2024US 12,161,097 B2Regeneron Pharmaceuticals, Inc.
- Method for producing platelets using reciprocating stirring device22 Oct 2024US 12,121,543 B2Megakaryon Corporation
- Minimal UTR sequences14 May 2024US 11,981,910 B2ethris GmbH
- Chimeric antigen receptors targeted to psca20 Aug 2026US 2026/0242509 A1City of Hope
- Animal models of reccurrent hepatocellular carcinoma and uses thereof27 Feb 2025US 2025/0064033 A1Centre for Oncology and Immunology Limited
- Chimeric antigen receptors targeted to psca2 Nov 2023US 2023/0348617 A1City of Hope
- Novel minimal utr sequences23 Mar 2023US 2023/0086606 A1ethris GmbH
- Systems and methods for in vivo dual recombinase-mediated cassette exchange (drmce) and disease models thereof16 Mar 2023US 2023/0084201 A1Cedars-Sinai Medical Center
Most cited
By later US patents
- Non-human animals having a humanized signal-regulatory protein gene29US 9,127,292 B2Regeneron Pharmaceuticals, Inc. · 2015
- Non-human animals having a humanized signal-regulatory protein gene29US 9,193,977 B2Regeneron Pharmaceuticals, Inc. · 2015
- Non-human animals having a humanized signal-regulatory protein gene28US 9,462,794 B2Regeneron Pharmaceuticals, Inc. · 2016
- Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes10US 8,722,964 B2Transposagen Biopharmaceuticals, Inc. · 2014
- Non-human animals having a humanized signal-regulatory protein gene5US 9,700,027 B2Regeneron Pharmaceuticals, Inc. · 2017